Fat, once viewed as a mere energy reservoir, has emerged as a multifaceted player in physiological signaling, including hormonal, nervous, and immune communications. Recent research spearheaded by Stanford Medicine sheds light on a novel aspect of adipose tissue – its involvement in promoting scarring in Crohn’s disease (CD) through a subtype termed “creeping fat” (CF).
Unlike its benign reputation, CF was discovered to instigate debilitating scarring within the intestines of individuals battling Crohn’s disease, exacerbating the progression of the condition. The resemblance between the mechanism of scar formation induced by CF and that seen in other tissues such as the skin intrigued researchers, hinting at a common fibrotic pathway across different anatomical sites.
Currently, the medical arsenal lacks precise therapeutics to impede scar development in CD patients, with surgical excision remaining the primary intervention. However, a recent study led by Jeong Hyun and Michael Longaker at Stanford Medicine identified potential molecular targets for novel drugs aimed at preventing the formation of strictures, offering a glimmer of hope for individuals grappling with the relentless burden of Crohn’s disease.
The study, published in Cell and titled “Creeping fat-derived mechanosensitive fibroblasts drive intestinal fibrosis in Crohn’s disease strictures,” sheds light on the pivotal role of CF in orchestrating intestinal fibrosis, marking a groundbreaking advancement in the understanding and management of CD-associated complications. Khristian E. Bauer-Rowe, an MD/PhD student at Stanford School of Medicine, spearheaded the research alongside collaborators from esteemed institutions such as Case Western Reserve University School of Medicine and the Icahn School of Medicine at Mt. Sinai.
Crohn’s disease, a debilitating gastrointestinal disorder with a predilection for the small intestine and bowel, poses significant challenges for patients due to its recurrent inflammatory nature. Despite the availability of anti-inflammatory agents to mitigate symptoms, the relentless progression of CD can culminate in the formation of strictures, constricting the intestinal lumen and severely impairing normal gastrointestinal function.
Strictures, a common complication affecting a substantial proportion of inadequately managed CD cases, contribute significantly to the morbidity associated with the disease. Surgical interventions, while offering temporary relief, are marred by high recurrence rates and the risk of diminishing viable intestinal tissue, underscoring the urgent need for targeted anti-fibrotic therapies to alleviate the burden on CD patients.
The research team’s meticulous analysis of human tissue samples, coupled with the development of a murine model mirroring CD pathophysiology, unveiled a distinct population of fibroblasts within CF that possess mechanosensitive properties, driving the relentless progression of intestinal fibrosis. By elucidating the genetic pathways underpinning CF-induced fibrotic responses, the study delineates a roadmap for potential therapeutic interventions targeting this pathological cascade.
Furthermore, the integration of multi-omics analyses and lineage tracing techniques in the mouse model provided invaluable insights into the intricate interplay between inflammation, mechanical strain, and fibroblast activation within the CF microenvironment. These findings not only deepen our understanding of CD pathogenesis but also pave the way for innovative therapeutic strategies aimed at disrupting the fibrotic cascade orchestrated by CF-derived fibroblasts.
The paradigm shift proposed by Hyun and Longaker, delineating an “outside-in” perspective on CD pathophysiology, challenges the conventional view of mucosa-centered inflammation, highlighting the pivotal role of adipose tissue in perpetuating the fibrotic sequelae of Crohn’s disease. Leveraging insights gleaned from their scarring research in other tissues, the team is optimistic about the translational potential of targeting mechanosensitive pathways to mitigate fibrosis in CD patients.
In conclusion, the groundbreaking findings presented in the study underscore the indispensable role of CF-derived fibroblasts in driving the progression of strictures in Crohn’s disease. By unraveling the intricate crosstalk between inflammation, mechanical tension, and adipose tissue signaling, the research not only sheds light on the enigmatic pathogenesis of CD but also offers a ray of hope for the development of precision anti-fibrotic therapies tailored to mitigate the burden of intestinal strictures in affected individuals.
Takeaways:
– “Creeping fat” emerges as a key player in driving fibrosis in Crohn’s disease, exacerbating intestinal scarring.
– Unveiling mechanosensitive fibroblasts within CF sheds light on novel therapeutic targets for preventing stricture formation in CD.
– The interplay between inflammation, mechanical strain, and adipose tissue signaling unveils a complex pathogenic cascade in Crohn’s disease.
– Targeting mechanosensitive pathways holds promise for future anti-fibrotic therapies in CD management.
Tags: biotech, clinical trials
Read more on genengnews.com